Can a weekly diabetes drug speed recovery from dangerous low blood sugar?
NCT ID NCT06982846
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 study tested whether a weekly injection of retatrutide helps people with type 2 diabetes recover faster from low blood sugar (hypoglycemia). 80 participants on metformin and diet/exercise received either retatrutide or a placebo for 16 weeks. Researchers measured how quickly blood sugar returned to a safe level after being lowered in a controlled setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
retatrutide (a weekly injection)
What this could lead to
If it works, this could show that retatrutide helps people with type 2 diabetes recover more quickly from dangerously low blood sugar.
What could go wrong
This is a small, early-phase trial (80 people) that measures a specific lab response, not real-world outcomes. The results may not apply to all patients or lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Universität Graz
Graz, 8010, Austria